Back to Journals » International Journal of Nephrology and Renovascular Disease » Volume 12

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives

Authors Rodenburg RJ, Eskens FALM

Received 10 October 2018

Accepted for publication 3 April 2019

Published 15 May 2019 Volume 2019:12 Pages 137—141

DOI https://doi.org/10.2147/IJNRD.S169056

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 3

Editor who approved publication: Professor Pravin Singhal


RJ Rodenburg, FALM Eskens

Erasmus MC Cancer Institute, Department of Medical Oncology, Rotterdam, The Netherlands

Abstract: Tivozanib is an oral selective vascular endothelial growth factors receptor (VEGFR) tyrosine kinase inhibitor that is recently approved by the European Medicines Agency for the treatment of previously untreated patients with metastatic renal cell carcinoma (mRCC) as well as for those patients with disease progression during or after cytokine therapy. Nowadays, in first-line and second-line treatment of mRCC, there is an abundance of options, mainly consisting of VEGFR-directed tyrosinekinase inhibitors. This review focusses on the role of tivozanib with respect to patient selection and future perspectives in this fast-changing landscape.

Keywords: tivozanib, metastatic renal cell cancer, tyrosine kinase inhibitor


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]